because rigorously controlled human safety data specific to the TB-500 fragment does not exist, its longer-term risk profile, including possible immune reactions, remains unknown Evidence snapshot: Evidence for TB-500 itself is preclinical, drawn mainly from cell-culture and animal studies (a 1999 rat wound-healing study and later rodent cardiac- and tendon-injury models), with a 2026 scoping review describing the musculoskeletal literature on thymosin beta-4 and TB-500 as sparse and largely preclinical
However, limitations exist in the form of in vivo instability, the reliance on carriers that are biocompatible and robust and limited sites of application (local and direct) (Park et al
M.Van der HeijdenI.HendriksW
Many peptides are compounded medications and not FDA-approved for all indications
The regimen may be changed or stopped if the therapy isnt working by weeks 8 to 12, if the patient has a new medical condition, or if side effects become bothersome
Genetic and Hormonal Factors: Genetic predisposition or hormonal imbalances can facilitate weight gain in some people
